Better performance of CARs deprived of the PD-1 brake.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24004672.
- Also identified by DOI 10.1158/1078-0432.CCR-13-2157.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunotherapies often permit combinations to increase efficacy. Two approaches are currently leading our field: adoptive therapy with T cells transfected with chimeric antigen receptors and monoclonal antibodies blocking the PD-1/PD-L1 (B7-H1) axis. In this issue of Clinical Cancer Research, preclinical evidence for a synergistic combination of such approaches is reported.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Neoplasms
- Programmed Cell Death 1 Receptor
- T-Lymphocyte Subsets